Literature DB >> 23716548

Expression of CD8 is associated with non-common type morphology and outcome in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.

Dmitriy Abramov1, Ilske Oschlies, Martin Zimmermann, Dmitriy Konovalov, Christine Damm-Welk, Wilhelm Wössmann, Wolfram Klapper.   

Abstract

Anaplastic lymphoma kinase-positive anaplastic large T-cell lymphoma is characterized by morphological variability. Morphological variants (non-common subtype) are associated with a poor outcome. They display abundant reactive bystander cells admixed with the lymphoma cells. So far, the difficulty in distinguishing lymphoma cells from bystander cells by visual inspection has prevented detailed and reliable immunophenotypic analysis using conventional immunohistochemistry. To overcome these limitations, we analyzed 124 cases of pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma treated within clinical trials using immunofluorescence multi-staining and digital image analysis combining antibodies against anaplastic lymphoma kinase to specifically identify lymphoma cells with antibodies against CD30, CD3, CD5, CD8, Ki67 and phosphorylated STAT3. Non-common type anaplastic lymphoma kinase-positive anaplastic large cell lymphomas express CD8 more frequently than common type anaplastic lymphoma kinase-positive anaplastic large cell lymphomas (35.4% and 5.6%, respectively; P=0.0002). CD8 expression was associated with a poorer outcome. Importantly, in a multivariate analysis including clinical risk factors, histological subtype and CD8 expression, CD8-positivity proved to be an independent prognostic predictor of worse outcome (hazard ratio for survival 3.38, P=0.042).

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23716548      PMCID: PMC3789459          DOI: 10.3324/haematol.2013.085837

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  31 in total

Review 1.  Molecular interactions of coreceptor CD8 and MHC class I: the molecular basis for functional coordination with the T-cell receptor.

Authors:  G F Gao; B K Jakobsen
Journal:  Immunol Today       Date:  2000-12

Review 2.  CD30(+) anaplastic large cell lymphoma: a review of its histopathologic, genetic, and clinical features.

Authors:  H Stein; H D Foss; H Dürkop; T Marafioti; G Delsol; K Pulford; S Pileri; B Falini
Journal:  Blood       Date:  2000-12-01       Impact factor: 22.113

3.  Immunophenotypic analysis of anaplastic large cell lymphoma by flow cytometry.

Authors:  Jonathan Juco; Jeannine T Holden; Karen P Mann; Lloyd G Kelley; Shiyong Li
Journal:  Am J Clin Pathol       Date:  2003-02       Impact factor: 2.493

4.  A small cell variant of ALK-positive, CD8-positive anaplastic large cell lymphoma with primary subcutaneous presentation mimicking subcutaneous panniculitis-like T-cell lymphoma.

Authors:  Endi Wang; John Papalas; Imran Siddiqi; Maggie Stoecker; Catherine Rehder; Siby Sebastain; Jim Burchette; Qin Huang
Journal:  Pathol Res Pract       Date:  2011-07-16       Impact factor: 3.250

5.  Prevalence and clinical implications of bone marrow involvement in pediatric anaplastic large cell lymphoma.

Authors:  L Mussolin; M Pillon; E S d'Amore; N Santoro; A Lombardi; F Fagioli; L Zanesco; A Rosolen
Journal:  Leukemia       Date:  2005-09       Impact factor: 11.528

6.  Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study.

Authors:  Willi Woessmann; Martin Zimmermann; Meike Lenhard; Birgit Burkhardt; Claudia Rossig; Bernhard Kremens; Peter Lang; Andishe Attarbaschi; Georg Mann; Ilske Oschlies; Wolfram Klapper; Alfred Reiter
Journal:  J Clin Oncol       Date:  2011-06-27       Impact factor: 44.544

7.  Prognostic impact of morphologic and phenotypic features of childhood ALK-positive anaplastic large-cell lymphoma: results of the ALCL99 study.

Authors:  Laurence Lamant; Keith McCarthy; Emanuele d'Amore; Wolfram Klapper; Atsuko Nakagawa; Maximo Fraga; Jadwiga Maldyk; Ingrid Simonitsch-Klupp; Ilske Oschlies; Georges Delsol; Audrey Mauguen; Laurence Brugières; Marie-Cécile Le Deley
Journal:  J Clin Oncol       Date:  2011-11-14       Impact factor: 44.544

8.  Prognostic significance of CD56 expression for ALK-positive and ALK-negative anaplastic large-cell lymphoma of T/null cell phenotype.

Authors:  R Suzuki; Y Kagami; K Takeuchi; M Kami; M Okamoto; R Ichinohasama; N Mori; M Kojima; T Yoshino; H Yamabe; M Shiota; S Mori; M Ogura; N Hamajima; M Seto; T Suchi; Y Morishima; S Nakamura
Journal:  Blood       Date:  2000-11-01       Impact factor: 22.113

9.  Anaplastic large cell lymphomas: a study of 75 pediatric patients.

Authors:  E S G d'Amore; A Menin; E Bonoldi; P Bevilacqua; S Cazzavillan; V Donofrio; C Gambini; M Forni; A Gentile; G Magro; R Boldrini; M Pillon; A Rosolen; R Alaggio
Journal:  Pediatr Dev Pathol       Date:  2007 May-Jun

10.  Pathobiology of ALK-negative anaplastic large cell lymphoma.

Authors:  Stefano A Pileri; Claudio Agostinelli; Francesco Bacci; Elena Sabattini; Carlo Sagramoso; Brunangelo Falini; Pier Paolo Piccaluga
Journal:  Pediatr Rep       Date:  2011-06-22
View more
  4 in total

1.  Analysis of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-reactive CD8(+) T cell responses in children with NPM-ALK(+) anaplastic large cell lymphoma.

Authors:  V K Singh; S Werner; H Hackstein; V Lennerz; A Reiter; T Wölfel; C Damm-Welk; W Woessmann
Journal:  Clin Exp Immunol       Date:  2016-08-16       Impact factor: 4.330

2.  IL10RA modulates crizotinib sensitivity in NPM1-ALK+ anaplastic large cell lymphoma.

Authors:  Nina Prokoph; Nicola A Probst; Liam C Lee; Jack M Monahan; Jamie D Matthews; Huan-Chang Liang; Klaas Bahnsen; Ivonne A Montes-Mojarro; Elif Karaca-Atabay; Geeta G Sharma; Vikas Malik; Hugo Larose; Sorcha D Forde; Stephen P Ducray; Cosimo Lobello; Qi Wang; Shi-Lu Luan; Šárka Pospíšilová; Carlo Gambacorti-Passerini; G A Amos Burke; Shahid Pervez; Andishe Attarbaschi; Andrea Janíková; Hélène Pacquement; Judith Landman-Parker; Anne Lambilliotte; Gudrun Schleiermacher; Wolfram Klapper; Ralf Jauch; Wilhelm Woessmann; Gilles Vassal; Lukas Kenner; Olaf Merkel; Luca Mologni; Roberto Chiarle; Laurence Brugières; Birgit Geoerger; Isaia Barbieri; Suzanne D Turner
Journal:  Blood       Date:  2020-10-01       Impact factor: 22.113

3.  Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target.

Authors:  Hugo Larose; Nina Prokoph; Jamie D Matthews; Michaela Schlederer; Sandra Högler; Ali F Alsulami; Stephen P Ducray; Edem Nuglozeh; Feroze M S Fazaludeen; Ahmed Elmouna; Monica Ceccon; Luca Mologni; Carlo Gambacorti-Passerini; Gerald Hoefler; Cosimo Lobello; Sarka Pospisilova; Andrea Janikova; Wilhelm Woessmann; Christine Damm-Welk; Martin Zimmermann; Alina Federova; Andrea Malone; Owen Smith; Mariusz Wasik; Giorgio Inghirami; Laurence Lamant; Tom L Blundell; Wolfram Klapper; Olaf Merkel; Amos G A Burke; Shahid Mian; Ibraheem Ashankyty; Lukas Kenner; Suzanne D Turner
Journal:  Haematologica       Date:  2021-06-01       Impact factor: 9.941

Review 4.  Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma.

Authors:  Serena Stadler; Vijay Kumar Singh; Fabian Knörr; Christine Damm-Welk; Wilhelm Woessmann
Journal:  Cancers (Basel)       Date:  2018-04-10       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.